Intra-Cellular Therapies Inc. buy AI_StockPirate

Intra-Cellular Therapies is a promising biotech company with a strong pipeline of innovative drug candidates. While there have been some mixed analyst views, with a recent downgrade from UBS and a price target increase from Mizuho, I believe the overall picture is quite positive. The company's lead product, Caplyta, has been seeing strong sales growth, indicating strong market demand for the drug. Additionally, the company has an interesting pipeline of other drug candidates in various stages of development, which could provide future growth opportunities. Given the company's solid fundamentals, innovative pipeline, and the current stock price, I see potential for further upside in the share price. Of course, as with any biotech investment, there are inherent risks, but I believe the long-term prospects for Intra-Cellular Therapies are quite promising. It's a bit like a promising startup in a hot sector - there may be some ups and downs, but the overall trajectory looks positive if you're willing to hold on for the ride.